Cell penetrating peptides as efficient nanocarriers for delivery of antifungal compound, natamycin for the treatment of fungal keratitis

Pharmaceutical Research

Volumn 32, Issue 6, 2015, Pages 1920-1930

  Jain, Aastha ^a   Shah, Sushmita G ^b   Chugh, Archana ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY DELHI   (India)

^b Dr CM Shah Memorial Charitable Trust Netra Mandir ^*  (India)

Author keywords

Antifungal activity; Cell penetrating peptide; Corneal tissue; Drug delivery; Solubility

Indexed keywords

CELL PENETRATING PEPTIDE; NANOCARRIER; NATAMYCIN; ANTIFUNGAL AGENT; DRUG CARRIER;

ANTIFUNGAL ACTIVITY; ARTICLE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CORNEA CELL; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG SOLUBILITY; EPITHELIUM CELL; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; FUSARIUM SOLANI; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INTERNALIZATION; KERATOMYCOSIS; MTT ASSAY; PRIORITY JOURNAL; CHEMISTRY; CORNEA EPITHELIUM; DRUG EFFECTS; EYE INFECTIONS, FUNGAL; FUNGUS; HELA CELL LINE; KERATITIS; MEDICINAL CHEMISTRY; METABOLISM; MICROBIOLOGY; NANOTECHNOLOGY; PARTICLE SIZE; PHARMACEUTICS; PROCEDURES; SOLUBILITY;

ANTIFUNGAL AGENTS; CELL-PENETRATING PEPTIDES; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; EPITHELIUM, CORNEAL; EYE INFECTIONS, FUNGAL; FUNGI; HELA CELLS; HUMANS; KERATITIS; NANOTECHNOLOGY; NATAMYCIN; PARTICLE SIZE; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 84934999795     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1586-x     Document Type: Article

References (38)

1. Thomas PA. Fungal infections of the cornea. Eye. 2003;17(8):852-62.
2. Thomas PA, Kaliamurthy J. Mycotic Keratitis: epidemiology, diagnosis and management. Clin Microbiol Infect. 2013;19(3):210-20.
3. Al-Badriyeh D, Neoh CF, Stewart K, Kong DC. Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis. Clin Ophthalmol. 2010;4:391-405.
4. Leck AK, Thomas PA, Hagan M, Kaliamurthy J, Ackuaku E, John M, et al.Aetiology of suppurative corneal ulcers in Ghana and south India, and epidemiology of fungal keratitis. Br J Ophthalmol. 2002;86(11):1211-5.
5. Gopinathan U, Garg P, FernandesM, Sharma S, Athmanathan S, Rao GN. The epidemiological features and laboratory results of fungal keratitis: a 10-year review at a referral eye care center in South India. Cornea. 2002;21(6):555-9.
6. Gopinathan U, Sharma S, Garg P, Rao GN. Review of epidemiological features, microbiological diagnosis and treatment outcome of microbial keratitis: experience of over a decade. Indian J Ophthalmol. 2009;57(4):273-9.
7. Whitcher JP, SrinivasanM,Upadhyay P. Corneal blindness: a global perspective. Bull World Health Organ. 2001;79(3):214-21.
8. Lalitha P, Sun CQ, Prajna NV, Karpagam R, Geetha M, O'Brien KS, et al. In vitro susceptibility of filamentous fungal isolates from a corneal ulcer clinical trial. Am J Ophthalmol. 2014;157(2):318-26.
9. Burton MJ, Pithuwa J, Okello E, Afwamba I, Onyango JJ, Oates F, et al. Microbial Keratitis in East Africa: why are the outcomes so poor? Ophthalmic Epidemiol. 2011;18(4):158-63.
10. Keay LJ, Gower EW, Lovieno A,Oechsler RA, Alfonso EC, Matoba A, et al. Clinical and microbiological characteristics of Fungal Keratitis in the United States, 2001-2007: A Multicenter Study. Ophthalmology. 2011;118(5):920-6.
11. Phan CM, Subbaraman LN, Jones L. In vitro uptake and release of natamycin from conventional and silicone hydrogel contact lens materials. Eye Contact Lens. 2013;39(2):162-8.
12. Ciolino JB,Hudson SP, Mobbs AN, Hoare TR, IwataNG, FinkGR, et al. A prototype antifungal contact lens. Invest Ophthalmol Vis Sci. 2011;52(9):6286-91.
13. Loh AR, Hong K, Lee S, Mannis M, Acharya NR. Practice patterns in the management of fungal corneal ulcers. Cornea. 2009;28(8): 856-9.
14. O'day DM, Ray WA, Head WS, Robinson RD. Influence of the corneal epithelium on the efficacy of topical antifungal agents. Invest Ophthalmol Vis Sci. 1984;25(7):855-9.
15. O'day DM, Head WS, Robinson RD, Clanton JA. Corneal penetration of topical amphotericin B and natamycin. Curr Eye Res. 1986;5(11):877-82.
16. Waltman SR, Kaufman HE. Use of hydrophilic contact lenses to increase ocular penetration of topical drugs. Invest Ophthalmol Vis Sci. 1970;9(4):250-5.
17. Xie L, ZhongW, Shi W, Sun S. Spectrumof fungal keratitis in north China. Ophthalmology. 2006;113(11):1943-8.
18. Phan CM, Subbaraman L, Liu S, Gu F, Jones L. In vitro uptake and release of natamycin Dex-b-PLA nanoparticles from model contact lens materials. J Biomater Sci Polym Ed. 2014;25(1):18-31.
19. Panyam J, Labhasetwar V. Dynamics of endocytosis and exocytosis of poly(D, L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm Res. 2003;20(2):212-20.
20. Vasir JK, Labhasetwar V. Quantification of the force of nanoparticle-cell membrane interactions and its influence on intracellular trafficking of nanoparticles. Biomaterials. 2008;29(31):4244-52.
21. Desai P, Patlolla RR, Singh M. Interaction of nanoparticles and cell penetrating peptides with skin for transdermal drug delivery. Mol Membr Biol. 2010;27(7):247-59.
22. Trabulo S, Cardoso AL, Mano M, De Lima Pedroso MC. Cellpenetrating peptides-mechanisms of cellular uptake and generation of delivery systems. Pharmaceuticals. 2010;3:961-93.
23. Gupta B, Levchenko TS, Torchilin VP. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev. 2005;57(4):637-51.
24. Simeoni F, Morris MC, Heitz F, Divita G. Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res. 2003;31(11):2717-24.
25. Aroui S, BrahimS,WaardMD, Kenani A.Cytotoxicity, intracellular distribution and uptake of doxorubicin and doxorubicin coupled to cell-penetrating peptides in different cell lines: a comparative study. Biochem Biophys Res Commun. 2010;391(1):419-25.
26. Ruan G, Agrawal A, Marcus AI, Nie S. Imaging and tracking of tat peptide-conjugated quantum dots in living cells: new insights into nanoparticle uptake, intracellular transport, and vesicle shedding. J Am Chem Soc. 2007;129(47):14759-66.
27. Liu L, Guo K, Lu J, Venkatraman SS, Luo D, Ng KC, et al. Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. Biomaterials. 2008;29(10):1509-17.
28. Cohen-Avrahami M, Shames A, Ottaviani MF, Aserin A, Garti N. HIV-Tat enhances the transdermal delivery of NSAID drugs from liquid crystalline mesophases. J Phys Chem B. 2014;118(23):6277-87.
29. Ookubo N, Michiue H, Kitamatsu M, Kamamura M, Nishiki T, Ohmori I, et al. The transdermal inhibition of melanogenesis by a cell-permeable peptide delivery system based on poly-arginine. Biomaterials. 2014;35(15):4508-16.
30. Wang Y, Su W, Li Q, Li C, Wang H, Li Y, et al. Preparation and evaluation of lidocaine hydrochloride loaded TAT-conjugated polymeric liposomes for transdermal delivery. Int J Pharm. 2013;441(1-2):748-56.
31. Manosroi J, Khositsuntiwong N, Manosroi W, Gotz F, Werner RG, Manosroi A. Potent enhancement of transdermal absorption and stability of human tyrosinase plasmid (pAH7/Tyr) by Tat peptide and an entrapment in elastic cationic niosomes. Drug Deliv. 2013;20(1):10-8.
32. Clinical and Laboratory Standards Institute, Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard CLSI document M38-A2, Clinical and Laboratory Standards Institute, Wayne, PA (2008)
33. Badhani A, Dabral P, Rana V, Upadhyaya K. Evaluation of cyclodextrins for enhancing corneal penetration of natamycin eye drops. J Pharm Bioallied Sci. 2012;4 Suppl 1:S29-30.
34. Salvosa FAM, Cubillan LP. In vitro evaluation of natamycin 5% suspension against Aspergillus flavus, Fusarium solani, and Candida parasilopsis. Ophthalmology. 2004;29(1):26-8.
35. Chugh A, Eudes F. Translocation and nuclear accumulation of monomer and dimer of HIV-1 Tat basic domain in triticale mesophyll protoplasts. Biochim Biophys Acta. 2007;1768(3):419-26.
36. Kanduser M, Sentjurc M, Miklavcic D. The temperature effect during pulse application on cell membrane fluidity and permeabilization. Bioelectrochemistry. 2008;74(1):52-7.
37. Zhu WL, Shin SY. Effects of dimerization of the cell penetrating peptide Tat analog on antimicrobial activity and mechanism of bactericidal action. J Pept Sci. 2009;15(5):345-52.
38. Jung HJ, Park Y, Hahm KS, Lee DG. Biological activity of Tat (47-58) peptide on human pathogenic fungi. Biochem Biophys Res Commun. 2006;345(1):222-8.